208 related articles for article (PubMed ID: 11547528)
21. Arsenic-induced APL differentiation in cerebrospinal fluid.
Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
[TBL] [Abstract][Full Text] [Related]
22. [Arsenic efficient in acute promyelocytic leukemia].
Lehmann S; Paul C
Lakartidningen; 1999 Dec; 96(50):5626-8. PubMed ID: 10643228
[TBL] [Abstract][Full Text] [Related]
23. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
24. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ
Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564
[TBL] [Abstract][Full Text] [Related]
25. Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia.
George B; Mathews L; Balasubramanian P; Shaji RV; Srivastava A; Chandy M
Haematologica; 2004 Oct; 89(10):1266-7. PubMed ID: 15477216
[TBL] [Abstract][Full Text] [Related]
26. Relationship between cytokines and leukocytosis in patients with APL induced by all-trans retinoic acid or arsenic trioxide.
Bi KH; Jiang GS
Cell Mol Immunol; 2006 Dec; 3(6):421-7. PubMed ID: 17257495
[TBL] [Abstract][Full Text] [Related]
27. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
Ducas RA; Seftel MD; Ducas J; Seifer C
J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
[TBL] [Abstract][Full Text] [Related]
28. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
29. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
30. Treatment of acute promyelocytic leukemia with arsenic trioxide.
Tamm I; Paternostro G; Zapata JM
N Engl J Med; 1999 Apr; 340(13):1043; author reply 1044-5. PubMed ID: 10189285
[No Abstract] [Full Text] [Related]
31. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
Kiguchi T; Yoshino Y; Yuan B; Yoshizawa S; Kitahara T; Akahane D; Gotoh M; Kaise T; Toyoda H; Ohyashiki K
Leuk Res; 2010 Mar; 34(3):403-5. PubMed ID: 19733394
[TBL] [Abstract][Full Text] [Related]
32. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Sasaki M; Sugimoto K; Isobe Y; Oshimi K
Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
[No Abstract] [Full Text] [Related]
33. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
34. Morphological and biochemical changes induced by arsenic trioxide in neuroblastoma cell lines.
Ryu KH; Woo SY; Lee MY; Jung YJ; Yoo ES; Seoh JY; Kie JH; Shin HY; Ahn HS
Pediatr Hematol Oncol; 2005; 22(7):609-21. PubMed ID: 16166054
[TBL] [Abstract][Full Text] [Related]
35. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
36. Arsenic trioxide: safety issues and their management.
Au WY; Kwong YL
Acta Pharmacol Sin; 2008 Mar; 29(3):296-304. PubMed ID: 18298894
[TBL] [Abstract][Full Text] [Related]
37. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Sanz MA; Fenaux P; Lo Coco F;
Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847
[TBL] [Abstract][Full Text] [Related]
38. Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission.
Tavernier E; Thomas X
Indian J Cancer; 2003; 40(4):140-3. PubMed ID: 14716110
[TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
Zappasodi P; Rossi M; Ambaglio I; Bernasconi P; Corso A; Lazzarino M; Castagnola C
Ann Hematol; 2011 May; 90(5):595-7. PubMed ID: 20721555
[No Abstract] [Full Text] [Related]
40. Anion exchanger 2 mediates the action of arsenic trioxide.
Pan XY; Chen GQ; Cai L; Buscemi S; Fu GH
Br J Haematol; 2006 Sep; 134(5):491-9. PubMed ID: 17018029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]